EyeYon Medical is a commercial ophthalmic company developing innovative solutions for corneal diseases. Our portfolio includes EndoArt®, a synthetic, donor-independent endothelial implant for chronic corneal edema, and Hyper-CL™, a unique therapeutic contact lens designed to enhance drug absorption and treat corneal pathologies more effectively.

Founded by ophthalmologists and industry experts, EyeYon is best known for its flagship product, the EndoArt®. EndoArt® expands treatment possibilities for selected patients with chronic corneal edema when endothelial transplantation has failed, is unsuitable or unavailable. EyeYon is committed to advancing ophthalmic technologies that improve outcomes, reduce reliance on donor tissue, and make vision care more accessible worldwide.

EyeYon Medical team

At EyeYon, we are building
a clearer future

EndoArt® Around The World

Map of countries where EndoArt® is used

United Kingdom

Switzerland

Spain

Netherlands

Japan

Italy

Israel

Greece

Germany

France

Denmark

Austria

Our Team

Nahum Ferera

Nahum Ferera, MBA

CEO, Co-founder

Mr. Nahum Ferera is an entrepreneur who specializes in leading medical device projects from idea to a successful product. Nahum founded EyeYon Medical together with Dr. Daphna and Dr. Marcovich in 2010 and has served as CEO from the start. Nahum led the commercialisation of EyeYon’s first product – the Hyper-CL™ – from idea to CE approval and FDA clearance, and has extensive experience in c-level management, ophthalmic medical devices, business development, clinical trials, regulation and intellectual property. Prior to EyeYon Medical, Nahum led a project in non-invasive blood glucose monitoring, successfully passing clinical trials and resulting in a granted patent. His experience includes developing medical devices in the field of cardiac rate management based on MEMS technology.

Dr. Ofer Daphna

Dr. Ofer Daphna, MD

Chief Medical Officer, Co-founder

Dr. Ofer Daphna is an inventor, entrepreneur and researcher, owner of several patents in the field of ophthalmology. He specialized in corneal and cataract surgery and is currently a senior Ophthalmologist at Assuta medical center, Tel-Aviv, Israel. Ofer is a high-volume cataract and corneal surgeon, conducting over 1000 operation per year (about 800 cataract and 300 corneal & refractive surgeries). He is the inventor of the EndoArt implant and the Hyper-CL™ therapeutic contact lens, as well as a co-founder of EyeYon Medical. Besides serving as Chief Medical Officer, he is also a Board Member. Ofer has performed about 150 animal operations on pigs and rabbits, and is responsible for training surgeons in the EndoArt® procedure.

Dr. Malca Chen Zion

Dr. Malca Chen Zion, PhD

Clinical and Regulatory Director

Charles Holmes

Charles Holmes

Chief Commercial Officer

Charles has pursued a highly successful career in the pharma industry globally with over 25 years of experience, including senior positions in ophthalmology with Bayer, Allergan and Alcon. Most recently as VP and Global Head of Ophthalmology at Allergan.  While at Bayer, Charles was part of the global strategic marketing team responsible for launching Eylea® in the US and ROW markets.  Charles holds a Bachelor of Science degree from California State University.  Charles is nominated as EyeYon Medical’s Chief Commercial Officer to establish commercialization strategy for EyeYon’s overall products. *Contractor

Limor Kuznits

Limor Kuznits

VP Clinical Affairs & Development

Anat Lemze

Anat Lemze, MBA

Director, Medical Affairs

Dmitry Dubson

Dmitry Dubson, MSc

Chief Technology Officer

Mr. Dmitry Dubson has 16 years of experience in the medical device industry. He specialises in products development from concept to marketplace and led projects in the field of vascular implants, hernia meshes, drug delivery and wound care devices.

Dmitry has participated in a few EU projects, including development of a new therapy for glaucoma treatment, development of a biomimetic nano-polymer based gel for minimally invasive disc regeneration treatment, and development of personalized wound dressing based on nanofiber mats.

Dmitry is responsible for planning and executing the NPD pipeline from concept stage through production, defining product development milestones and the required budget. Dmitry is responsible for recruitment and management of R&D team and distribution of human resources. He coordinates tasks with other company departments, subcontractors and consultants, plans and executes V&V programs, monitors manufacturing and QC processes.

Dmitry is involved in annual budget preparation, costs forecasting, and short/long term production scheduling.

Dmitry holds a MSc in Electro-Optical Engineering from Ben-Gurion University.

Ethan Nash

Ethan Nash, CPA

Chief Financial Officer

Ethan is a certified public accountant with over 20 years of financial and business management experience in private and publicly traded medical device and healthcare organizations.  Experienced in new business development, growth management, strategy execution while leading financial activities at a global level.

Ethan leads EyeYon’s financial, legal and operational activities.  Ethan holds a B.A. in Accounting and Economics from Tel-Aviv University.

Hagit Rudich Wilf

Hagit Rudich Wilf, MSc

Quality Assurance Director

Prof. Arie Marcovich

Prof. Arie Marcovich, MD

Co-Founder

Prof. Marcovich is Co-founder of EyeYon Medical, Head of Israeli cornea society, Deputy of the department of ophthalmology and senior ophthalmologist at the Kaplan Medical Centre. He is a specialist in corneal surgery at the University of Toronto, Canada. A former chairperson of the Israel Society of Cataract Surgeons, Dr. Marcovich conducts research at the Weizmann Institute of Science on corneal diseases. Dr. Marcovich has implemented the Endoart® in animals and led the Hyper-CL™ first clinical trial. He has presented his experience using both products at multiple meetings and conferences.

Prof. Hong Jing

Prof. Hong Jing, MD

SAB Member

Prof. Hong is Deputy Director of the department of ophthalmology at Peking University, Third Hospital, Professor, Chief Physician, doctoral tutor, director of the cornea ocular surface disease department, eye bank director, and committee member of the Chinese Ophthalmological Society Corneal Disease Group. She has published more than 100 papers in reputed journals. Prof. Hong was the PI of the first Hyper-CL™ Therapeutic contact lens trial in China, implanted the EndoArt® implant in animals, and led the EndoArt® clinical trial in China.

Deepinder K. Dhaliwal

Deepinder K. Dhaliwal, MD, L.Ac

SAB Member

Deepinder K. Dhaliwal, MD, L.Ac, is a professor of ophthalmology at the University of Pittsburgh
School of Medicine, chief of Refractive Surgery and the co-director of the Cornea Service at the
UPMC Eye Center. She is vice chair of the department of ophthalmology for wellness and
communications. Dr. Dhaliwal also serves as the director of the UPMC Laser Vision Center, the
associate medical director of the Campbell Ophthalmic Microbiology Laboratory and the clinical
co-director of the Corneal Regeneration Laboratory at the University of Pittsburgh.
Dr. Dhaliwal earned her medical degree from Northwestern University in the Honors Program in
Medical Education where she was selected to be a member of the prestigious Alpha Omega
Alpha Honor Society. She completed her residency in ophthalmology at the University of
Pittsburgh Medical Center where she was selected as chief resident her final year. She then
pursued fellowship training in cornea and refractive surgery at the University of Utah. She
became a licensed acupuncturist in 2006 and founded the Center for Integrative Eye Care at the
University of Pittsburgh to research integrative treatments for eye disease.
Dr. Dhaliwal holds leadership positions in the Cornea Society, the International Society of
Refractive Surgery of the American Academy of Ophthalmology, and the Eye and Contact Lens
Association/CLAO. Dr. Dhaliwal is a recognized expert in her field and teaches corneal and
refractive surgical techniques to other ophthalmologists globally. In addition to teaching and
research activities, she has authored several book chapters, numerous journal articles, and
serves on the editorial board of several ophthalmology journals. In recognition of her clinical
and surgical skills, she has been selected as a “Top Doctor” by her peers every year since
2006. She was selected to be on the ​Power List 100 in The Ophthalmologist (“Top 100 most
influential people in the world of ophthalmology”), and received the ​International Society of
Refractive Surgery Casebeer Award for outstanding contribution to research and development
of refractive surgery.
Prof. Doyle Stulting

Prof. Doyle Stulting, MD

SAB Member

Currently practicing at the Wolfson Eye Institute, a large private ophthalmology group, Prof. Stulting is past president of ASCRS, former director of Emory University’s refractive surgery center, former editor-in-chief of Cornea, and a board member of the EBAA. Prof. Stulting has implemented the EndoArt® in animals and presented his experience at international conferences.

Dr. Francis S. Mah

Dr. Francis S. Mah

SAB Member

Dr. Francis Mah received his medical degree from The University of Toledo College of Medicine and Life Sciences and Life Sciences and completed his residency at the University of Pittsburgh. As an #ophthalmologist with more than 20 years experience and comprehensive expertise Dr. Francis Mah is specialized in advanced #corneal, #cataract and #refractive surgery. He holds leadership positions in various ophthalmology associations and societies. Next to teaching cataract surgery and #LASIK at various academy and society meetings worldwide, Dr. Mah is a popular speaker and valued educator who has shared his expertise in more than 200 lectures and clinical publications. As an international expert on corneal infections, Dr. Mah is an advocate for using the latest techniques to ensure the best possible treatment for his patients.

Prof. Natalie Afshari

Prof. Natalie Afshari

SAB Member

Prof. Natalie Afshari, is Chief of Cornea and Refractive Surgery at the UC San Diego Shiley Eye Institute, USA and a proficient clinician, surgeon and research #cientist. Prof. Afshari received her medical degree from Stanford University and completed her residency and fellowship training at Harvard University. As a highly skilled cataract surgeon and recognized expert in corneal transplantation and refractive surgery, Prof. Afshari has been honored with multiple awards for her work. Her extensive list of accomplishments reach from several recognitions in “best doctors“ lists for her clinical practice, to honors for her numerous publications in medical and scientific journals and her commitment to teaching and training ophthalmologists. Prof. Afshari is also a member of several scientific committees and organizations. The US Food and Drug Administration (FDA) has relied on her expertise in the safety and efficacy of various #ophthalmologic treatments.

Prof. Arie Marcovich

Prof. Arie Marcovich, MD

Co-Founder

Dr. Ofer Daphna

Dr. Ofer Daphna, MD

Chief Medical Officer, Co-founder

Dmitry Dubson

Dmitry Dubson, MSc

Chief Technology Officer

Nahum Ferera

Nahum Ferera, MBA

CEO, Co-founder

Charles Holmes

Charles Holmes

Chief Commercial Officer

Prof. Arie Marcovich

Ethan Nash, CPA

Chief Financial Officer

Diamond Biofund
Triventures
Docor
Pontifax
Van Leer
Jerusalem Development Authority
CRCP Life Science Fund
Sagam Group
Rimonci
Mor Research Applications
Quark Venture

Our Products

EndoArt® Artificial Endothelial Layer
EndoArt® implant

Expanding Treatment Options
for Chronic Corneal Edema

EndoArt® corneal artificial endothelial layer is a synthetic, donor-independent implant designed to reduce chronic corneal edema, with treatment planned around patient needs rather than donor-tissue availability.

Hyper-CL™ Premium Therapeutic Contact Lens

Innovative Drug
Depot for Enhanced Topical Bioavailability

Hyper-CL™ therapeutic soft contact lens

Hyper-CL™ Therapeutic Soft Contact Lens is the first ocular drug depot system designed to enhance the bioavailability of topical drops. Its innovative design prolongs contact time on the cornea, improving treatment efficacy. CE-approved for continuous wear, Hyper-CL™ is clinically proven to relieve corneal conditions and is being commercialized across Europe and Asia.